



BlueCross BlueShield
of Alabama

Name of Blue Advantage Policy:

Autologous Chondrocyte Implantation for Focal Articular Cartilage Lesions

Policy #: 156

Latest Review Date: April 2022

Category: Surgery

BACKGROUND:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

1. *Safe and effective;*
2. *Not experimental or investigational*;*
3. *Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
 - *Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
 - *Furnished in a setting appropriate to the patient's medical needs and condition;*
 - *Ordered and furnished by qualified personnel;*
 - *One that meets, but does not exceed, the patient's medical need; and*
 - *At least as beneficial as an existing and available medically appropriate alternative.*

Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

POLICY:

For dates of service on or after March 24, 2020:

Blue Advantage will treat **autologous chondrocyte implantation** as a **covered benefit** for the treatment of disabling full-thickness articular cartilage defects of the knee caused by acute or repetitive trauma, when all of the following criteria are met:

- The patient is skeletally mature with documented closure of growth plates and not considered an appropriate candidate for total knee arthroplasty or other reconstructive knee surgery (e.g., age greater than 15 and less than 55 years); AND
- Focal, full-thickness (grade III or IV) unipolar lesions of the patella or the weight-bearing surface of the femoral condyles or trochlea at least 1.5 cm² in size; AND
- Documented minimal to absent degenerative changes in the surrounding articular cartilage (Outerbridge grade II or less), and normal-appearing hyaline cartilage surrounding the border of the defect; AND
- Normal knee biomechanics or alignment and stability achieved concurrently with autologous chondrocyte implantation.

Blue Advantage will treat **autologous chondrocyte implantation** as a **non-covered benefit** and as **investigational** for all other joints, including talar, and any indications other than those listed above is therefore considered investigational.

Blue Advantage will treat **prophylactic harvesting of cells during other reconstructive or reparative procedures** for possible future implantation as a **non-covered benefit** and as **investigational**.

Effective for dates of service February 26, 2018 through March 23, 2020, refer to LCD L36954.

Effective for dates of service prior to February 26, 2018:

Blue Advantage will treat **autologous chondrocyte implantation** as a **covered benefit** for the treatment of disabling full-thickness articular cartilage defects of the knee caused by acute or repetitive trauma when **all** of the following criteria are met:

- Adolescent patients should be skeletally mature with documented closure of growth plates (e.g., 15 years or older). Adult patients should be too young to be considered an appropriate candidate for total knee arthroplasty or other reconstructive knee surgery (e.g., younger than 55 years); AND
- Focal, full-thickness (grade III or IV) unipolar lesions of the patella or the weight-bearing surface of the femoral condyles or trochlea at least 1.5 cm² in size; AND
- Documented minimal to absent degenerative changes in the surrounding articular cartilage (Outerbridge grade II or less), and normal-appearing hyaline cartilage surrounding the border of the defect; AND
- Normal knee biomechanics or alignment and stability achieved concurrently with autologous chondrocyte implantation.

Blue Advantage will treat **autologous chondrocyte implantation** as a **non-covered** benefit for **all other joints**, including talar, and any indications other than those listed above are therefore considered **investigational**.

Blue Advantage will treat **prophylactic harvesting of cells** during other reconstructive or reparative procedures for possible future implantation as a **non-covered benefit**.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

DESCRIPTION OF PROCEDURE OR SERVICE:

A variety of procedures are being developed to resurface articular cartilage defects. Autologous chondrocyte implantation (ACI) involves harvesting chondrocytes from healthy tissue, expanding the cells in vitro, and implanting the expanded cells into the chondral defect under a periosteal or fibrin patch. Second- and third- generation techniques include combinations of autologous chondrocytes, scaffolds, and growth factors. This procedure may be performed at the same time as other surgical procedures such as repair of tendons or ligaments, osteotomies for realignment of a joint, or meniscal allograft transplantation.

Damaged articular cartilage typically fails to heal on its own and can be associated with pain, loss of function, and disability, and may lead to debilitating osteoarthritis over time. These manifestations can severely impair an individual's activities of daily living and adversely affect the quality of life.

Conventional treatment options include debridement, subchondral drilling, microfracture, and abrasion arthroplasty. Debridement involves the removal of synovial membrane, osteophytes, loose articular debris, and diseased cartilage and is capable of producing symptomatic relief. Subchondral drilling, microfracture, and abrasion arthroplasty attempt to restore the articular surface by inducing the growth of fibrocartilage into the chondral defect. Compared with the original hyaline cartilage, fibrocartilage has less capability to withstand shock or shearing force and can degenerate over time, often resulting in the return of clinical symptoms. Osteochondral grafts and autologous chondrocyte implantation (ACI) attempt to regenerate hyaline-like cartilage and thereby restore durable function. Osteochondral grafts for the treatment of articular cartilage defects are discussed in Medical Policy #248, Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions.

With ACI, a region of healthy articular cartilage is identified and biopsied through arthroscopy. The tissue is sent to a facility licensed by the U.S. Food and Drug Administration (FDA) where it is minced and enzymatically digested, and the chondrocytes are separated by filtration. The

isolated chondrocytes are cultured for 11 to 21 days to expand the cell population, tested, and then shipped back for implantation. With the patient under general anesthesia, an arthrotomy is performed, and the chondral lesion is excised up to the normal surrounding cartilage. Methods to improve the first-generation ACI procedure have been developed, including the use of a scaffold or matrix-induced autologous chondrocyte implantation (MACI) composed of biocompatible carbohydrates, protein polymers, or synthetics. The only FDA-approved MACI product to date is supplied in a sheet, which is cut to size and fixed with fibrin glue. This procedure is considered technically easier and less time consuming than the first-generation technique, which required suturing of a periosteal or collagen patch and injection of chondrocytes under the patch.

Desired features of articular cartilage repair procedures are the ability (1) to be implanted easily, (2) to reduce surgical morbidity, (3) not to require harvesting of other tissues, (4) to enhance cell proliferation and maturation, (5) to maintain the phenotype, and (6) to integrate with the surrounding articular tissue. In addition to the potential to improve the formation and distribution of hyaline cartilage, use of a scaffold with MACI eliminates the need for harvesting and suture of a periosteal or collagen patch. A scaffold without cells may also support chondrocyte growth.

KEY POINTS:

The most recent literature update was performed through February 16, 2022.

Summary of Evidence

For individuals who have focal articular cartilage lesion(s) of the weight-bearing surface of the femoral condyles, trochlea, or patella who receive ACI, the evidence includes systematic reviews, randomized controlled trials, and prospective observational studies. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, and quality of life. There is a large body of evidence on ACI for the treatment of focal articular cartilage lesions of the knee. For large lesions, ACI results in better outcomes than microfracture, particularly in the long term. In addition, there is a limit to the size of lesions that can be treated with osteochondral autograft transfer, due to a limit on the number of osteochondral cores that can be safely harvested. As a result, ACI has become the established treatment for large articular cartilage lesions in the knee. In 2017, first-generation ACI with a collagen cover was phased out and replaced with an ACI preparation that seeds the chondrocytes onto a bioresorbable collagen sponge. Although the implantation procedure for this second-generation ACI is less technically demanding, studies to date have not shown improved outcomes compared with first-generation ACI. Some evidence has suggested an increase in hypertrophy (overgrowth) of the new implant that may exceed that of the collagen membrane covered implant. Long-term studies with a larger number of patients will be needed to determine whether this hypertrophy impacts graft survival. Based on mid-term outcomes that approximate those of first-generation ACI and the lack of alternatives, second-generation ACI may be considered an option for large disabling full-thickness cartilage lesions of the knee. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have focal articular cartilage lesions of joints other than the knee who receive ACI, the evidence includes systematic reviews of case series. Relevant outcomes are

symptoms, change in disease status, morbid events, functional outcomes, and quality of life. The greatest amount of literature is for ACI of the talus. Comparative trials are needed to determine whether ACI improves outcomes for lesions in joints other than the knee. The evidence is insufficient to determine the effects of the technology on health outcomes.

Practice Guidelines and Position Statements

American Academy of Orthopaedic Surgeons

In its 2010 guidelines on the diagnosis and treatment of osteochondritis dissecans (OCD), the American Academy of Orthopaedic Surgeons (AAOS) was unable to recommend for or against a specific cartilage repair technique in symptomatic skeletally immature or mature patients with an unsalvageable osteochondritis dissecans lesion. This recommendation of insufficient evidence was based on a systematic review that found four level IV studies that addressed cartilage repair techniques for an unsalvageable OCD lesion. Since each of the level IV articles utilized different techniques, different outcome measures, and differing lengths of follow-up, the work group deemed that the evidence for any specific technique was inconclusive.

National Institute for Health and Clinical Excellence

In 2018, the National Institute for Health and Care Excellence updated its 2005 guidance on the use of autologous chondrocyte implantation. The NICE recommendations are stated below: "... as an option for treating symptomatic articular cartilage defects of the femoral condyle and patella of the knee (International Cartilage Repair Society grade III or IV) in adults, only if:

- the person has not had previous surgery to repair articular cartilage defects;
- there is minimal osteoarthritic damage to the knee (as assessed by clinicians experienced in investigating knee cartilage damage using a validated measure for knee osteoarthritis); and
- the defect is over 2 cm²."

U.S. Preventive Services Task Force Recommendations

Not applicable.

KEY WORDS:

Autologous chondrocyte transplantation (ACT), autologous chondrocyte implant (ACI), articular cartilage, chondrocytes, Carticel[®], osteochondritis dissecans (OCD), ChondroCelect, BioCart II, Cartilix, MACI[®], Cartipatch, NeoCart, Hyalograft C

APPROVED BY GOVERNING BODIES:

The culturing of chondrocytes is considered by the U.S. Food and Drug Administration (FDA) to fall into the category of manipulated autologous structural (MAS) cells, which are subject to a biologic licensing requirement. In 1997, Carticel received FDA approval for the repair of clinically significant, "...symptomatic cartilaginous defects of the femoral condyle (medial lateral or trochlear) caused by acute or repetitive trauma..."

In 2016, MACI[®] (matrix-induced autologous chondrocyte implantation [ACI]; Vericel), received FDA approval for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients. MACI[®] consists of autologous chondrocytes which are cultured onto a bio-resorbable porcine-derived collagen membrane. In 2017, production of Carticel was phased out and MACI[®] is the only ACI product that is available in the U.S.

A number of other second-generation methods for implanting autologous chondrocytes in a biodegradable matrix are currently in development or testing or are available outside of the United States. They include Atelocollagen (Koken), a collagen gel; Bioseed[®] C (BioTissue Technologies), a polymer scaffold; CaReS (Ars Arthro), collagen gel; Cartilix (Biomet), a polymer hydrogel; Chondron (Sewon Cellontech), a fibrin gel; Hyalograft C (Fidia Advanced Polymers), a hyaluronic acid-based scaffold; NeoCart (Histogenics), an ACI with a 3-dimensional chondromatrix in a phase 3 trial; and Novocart[®]3D (Aesculap Biologics), a collagenchondroitin sulfate scaffold in a phase 3 trial. ChondroCelect[®] (TiGenix), characterized as a chondrocyte implantation with a completed phase 3 trial, uses a gene marker profile to determine in vivo cartilage-forming potential and thereby optimizes the phenotype (e.g., hyaline cartilage vs fibrocartilage) of the tissue produced with each ACI cell batch. Each batch of chondrocytes is graded based on the quantitative gene expression of a selection of positive and negative markers for hyaline cartilage formation. Both Hyalograft C and ChondroCelect[®] have been withdrawn from the market in Europe. In 2020, the FDA granted breakthrough status to Agili-C (CartiHeal, Ltd.), a proprietary biocompatible and biodegradable tapered-shape implant for the treatment of cartilage lesions in arthritic and non-arthritic joints that, when implanted into a pre-prepared osteochondral hole, acts as a 3D scaffold that potentially supports and promotes the regeneration of the articular cartilage and its underlying subchondral bone.

BENEFIT APPLICATION:

Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

CURRENT CODING:

CPT codes:

27412	Autologous chondrocyte implantation, knee
27899	Unlisted procedure, leg or ankle
29870-29887	Code range, arthroscopy of the knee

HCPCS:

J7330	Autologous cultured chondrocytes, implant
S2112	Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)

REFERENCES:

1. Abraamyan T, Johnson AJ, Wiedrick J, et al. Marrow Stimulation Has Relatively Inferior Patient-Reported Outcomes in Cartilage Restoration Surgery of the Knee: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Am J Sports Med.* Apr 23 2021: 3635465211003595.
2. American Academy of Orthopaedic Surgeons. Clinical practice guideline on the diagnosis and treatment of osteochondritis dissecans. 2010.
[//www.aaos.org/research/guidelines/OCD_guideline.pdf](http://www.aaos.org/research/guidelines/OCD_guideline.pdf).
3. Andriolo L, Merli G, Filardo G, et al. Failure of autologous chondrocyte implantation. *Sports Med Arthrosc Rev.* Mar 2017;25(1):10-18.
4. Bartlett W, Skinner JA, Gooding CR, et al. Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee: a prospective, randomised study. *J Bone Joint Surg Br.* May 2005; 87(5):640-645.
5. Basad E, Ishaque B, Bachmann G et al. Matrix-induced autologous chondrocyte implantation versus microfracture in the treatment of cartilage defects of the knee: a 2-year randomised study. *Knee Surg Sports Traumatol Arthrosc* 2010; 18(4):519-527.
6. Basad E, Wissing FR, Fehrenbach P, Rickert M, Steinmeyer J, Ishaque B. Matrix-induced autologous chondrocyte implantation (MACI) in the knee: clinical outcomes and challenges. *Knee Surg Sports Traumatol Arthrosc.* Dec 2015; 23(12):3729-3735.
7. Bin Abd Razak HR, Acharyya S, Tan SM, et al. Predictors of Midterm Outcomes after Medial Unicompartmental Knee Arthroplasty in Asians. *Clin Orthop Surg.* 2017 Dec;9(4).
8. Brittberg M, Recker D, Ilgenfritz J, et al. Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Five-Year Follow-up of a Prospective Randomized Trial. *Am J Sports Med.* 2018 May;46(6).
9. Clement ND, MacDonald D, Simpson AH. The minimal clinically important difference in the Oxford knee score and Short Form 12 score after total knee arthroplasty. *Knee Surg Sports Traumatol Arthrosc.* Aug 2014; 22(8): 1933-9.
10. Collins NJ, Misra D, Felson DT, et al. Measures of knee function: International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Knee Injury and Osteoarthritis Outcome Score (KOOS), Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS), Knee Outcome Survey Activities of Daily Living Scale (KOS-ADL), Lysholm Knee Scoring Scale, Oxford Knee Score (OKS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Activity Rating Scale (ARS), and Tegner Activity Score (TAS). *Arthritis Care Res (Hoboken).* 2011 Nov;63 Suppl 11:S208-28.

11. Copay AG, Eyberg B, Chung AS, et al. Minimum Clinically Important Difference: Current Trends in the Orthopaedic Literature, Part II: Lower Extremity: A Systematic Review. *JBJS Rev.* 2018 Sep;6(9).
12. Devitt BM, Bell SW, Webster KE, et al. Surgical treatments of cartilage defects of the knee: Systematic review of randomised controlled trials. *Knee.* Jun 2017;24(3):508-517.
13. Ebert JR, Fallon M, Wood DJ, et al. A prospective clinical and radiological evaluation at 5 years after arthroscopic matrix-induced autologous chondrocyte implantation. *Am J Sports Med.* Jan 2017;45(1):59-69.
14. Ebert JR, Fallon M, Zheng MH, et al. A randomized trial comparing accelerated and traditional approaches to postoperative weight-bearing rehabilitation after matrix-induced autologous chondrocyte implantation: findings at 5 years. *Am J Sports Med.* Jul 2012;40(7):1527-1537.
15. Ebert JR, Schneider A, Fallon M, et al. A comparison of 2-year outcomes in patients undergoing tibiofemoral or patellofemoral matrix-induced autologous chondrocyte implantation. *Am J Sports Dec* 2017; 45(14): 3243-3253.
16. Ebert JR, Smith A, Edwards PK, et al. Factors predictive of outcome 5 years after matrix-induced autologous chondrocyte implantation in the tibiofemoral joint. *Am J Sports Med.* Jun 2013;41(6):1245-1254.
17. Ebert JR, Smith A, Fallon M, et al. Incidence, degree, and development of graft hypertrophy 24 months after matrix-induced autologous chondrocyte implantation: association with clinical outcomes. *Am J Sports Med.* Sep 2015; 43(9):2208-2215.
18. Free online Modified Cincinnati Knee Rating System calculator. OrthoToolKit.<https://www.orthotoolkit.com/cincinnati/>.
19. Gou GH, Tseng FJ, Wang SH, et al. Autologous Chondrocyte Implantation Versus Microfracture in the Knee: A Meta-analysis and Systematic Review. *Arthroscopy.* Jan 2020; 36(1): 289-303.
20. Greco NJ, Anderson AF, Mann BJ, et al. Responsiveness of the International Knee Documentation Committee Subjective Knee Form in comparison to the Western Ontario and McMaster Universities Osteoarthritis Index, modified Cincinnati Knee Rating System, and Short Form 36 in patients with focal articular cartilage defects. *Am J Sports Med.* 2010 May;38(5).
21. Gusi N, Olivares PR, Rajendram R. The EQ-5D Health-Related Quality of Life Questionnaire [Abstract]. In: Preedy VR, Watson RR, eds. *Handbook of Disease Burdens and Quality of Life Measures.* New York: Springer; 2010:87-89.
22. Harris JD, Cavo M, Brophy R et al. Biological Knee Reconstruction: A Systematic Review of Combined Meniscal Allograft Transplantation and Cartilage Repair or Restoration. *Arthroscopy* 2011; 27(3):409-418.
23. Harris JD, Siston RA, Pan X, et al. Autologous chondrocyte implantation: a systematic review. *J Bone Joint Surg Am.* Sep 15 2010; 92(12):2220-2233.
24. Hu M, Li X, Xu X. Efficacy and safety of autologous chondrocyte implantation for osteochondral defects of the talus:a systematic review and meta-analysis. *Arch Orthop Trauma Surg.* Jun 14 2021.

25. Lee WC, Bin Abd Razak HR, Allen JC, et al. Achieving Minimum Clinically Important Difference in Oxford Knee Score and Short Form-36 Physical Component Summary Is Less Likely with Single-Radius Compared with Multiradius Total Knee Arthroplasty in Asians. *J Knee Surg*. Mar 2019; 32(3): 227-232.
26. Lee WC, Kwan YH, Chong HC, et al. The minimal clinically important difference for Knee Society Clinical Rating System after total knee arthroplasty for primary osteoarthritis. *Knee Surg Sports Traumatol Arthrosc*. Nov 2017; 25(11): 3354-3359.
27. Meyerkort D, Ebert JR, Ackland TR, et al. Matrix-induced autologous chondrocyte implantation (MACI) for chondral defects in the patellofemoral joint. *Knee Surg Sports Traumatol Arthrosc*. Oct 2014; 22(10):2522-2530.
28. Minas T, Gomoll AH, Rosenberger R et al. Increased failure rate of autologous chondrocyte implantation after previous treatment with marrow stimulation techniques. *Am J Sports Med* 2009; 37(5):902-908.
29. Minas T, Von Keudell A, Bryant T et al. The John Insall Award: A minimum 10-year outcome study of autologous chondrocyte implantation. *Clin Orthop Relat Res* 2014; 472(1):41-51.
30. Mistry H, Connock M, Pink J, et al. Autologous chondrocyte implantation in the knee: systematic review and economic evaluation. *Health Technol Assess*. Feb 2017;21(6):1-294.
31. Mundi R, Bedi A, Chow L, et al. Cartilage Restoration of the Knee: A Systematic Review and Meta-Analysis of Level 1 Studies. *Am J Sports Med*. Jul 2016; 44(7):1888-1895.
32. National Institute for Health and Care Excellence (NICE). Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee [TA508]. 2018; <https://www.nice.org.uk/guidance/TA508/chapter/1-Recommendations>.
33. Nawaz SZ, Bentley G, Briggs TWR et al. Autologous chondrocyte implantation in the knee. *J Bone Joint Surg Am* 2014; 96(10):824-830.
34. Niemeyer P, Pestka JM, Kreuz PC et al. Characteristic complications after autologous chondrocyte implantation for cartilage defects of the knee joint. *Am J Sports Med* 2008; 36(11):2091-2099.
35. Niemeyer P, Salzman G, Schmal H et al. Autologous chondrocyte implantation for the treatment of chondral and osteochondral defects of the talus: a meta-analysis of available evidence. *Knee Surg Sports Traumatol Arthrosc* 2012; 20(9):1696-1703.
36. Riboh JC, Cvetanovich GL, Cole BJ, Yanke AB. Comparative efficacy of cartilage repair procedures in the knee: a network meta-analysis. *Knee Surg Sports Traumatol Arthrosc*. Dec 2017; 25(12):3786-3799.
37. Roos EM, Engelhart L, Ranstam J, et al. ICRS Recommendation Document: Patient-Reported Outcome Instruments for Use in Patients with Articular Cartilage Defects. *Cartilage*. 2011 Apr;2(2).
38. Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. *Health Qual Life Outcomes*. 2003 Nov;1:64.
39. Sacolick DA, Kirven JC, Abouljoud MM, et al. The Treatment of Adult Osteochondritis Dissecans with Autologous Cartilage Implantation: A Systematic Review. *J Knee Surg*. 2019 Nov;32(11).

40. Saris D, Price A, Widuchowski W et al. Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-year follow-up of a prospective randomized trial. Am J Sports Med. Jun 2014; 42(6):1384-1394.
41. Schuette HB, Kraeutler MJ, McCarty EC. Matrix-assisted autologous chondrocyte transplantation in the knee: a systematic review of mid- to long-term clinical outcomes. Orthop J Sports Med. Jun 2017; 5(6):2325967117709250.
42. Shimoazono Y, Yasui Y, Ross AW, et al. Scaffolds based therapy for osteochondral lesions of the talus: A systematic review. World J Orthop. Oct 18 2017;8(10):798-808.
43. Zak L, Aldrian S, Wondrasch B, et al. Ability to return to sports 5 years after matrix-associated autologous chondrocyte transplantation in an average population of active patients. Am J Sports Med. Dec 2012; 40(12):2815-2821.
44. Zamborsky R, Danisovic L. Surgical Techniques for Knee Cartilage Repair: An Updated Large-Scale Systematic Review and Network Meta-analysis of Randomized Controlled Trials. Arthroscopy. Mar 2020; 36(3): 845-858.

POLICY HISTORY:

Adopted for Blue Advantage, March 2005

Available for comment May 1-June 14, 2005

Medical Policy Group, May 2007

Available for comment May 8-June 21, 2007

Medical Policy Group, December 2009

Available for comment December 4, 2009-January 19, 2010

Medical Policy Group, March 2010

Available for comment April 15-May 29, 2010

Medical Policy Group, June 2011

Available for comment July 6 through August 22, 2011

Medical Policy Group, June 2012

Medical Policy Group, June 2013

Available for comment June 27 through August 10, 2013

Medical Policy Group, September 2013

Medical Policy Group, June 2014

Medical Policy Group, June 2015

Medical Policy Group, October 2015

Available for comment October 29 through December 13, 2015

Medical Policy Group, April 2017

Available for comment April 26 through June 10, 2017

Medical Policy Group, December 2017

Medical Policy Group, April 2020: Reinstated policy effective March 24, 2020.

Medical Policy Group, January 2021

Medical Policy Group, April 2021

Medical Policy Group, April 2022

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date

Page 10 of 11

services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.